Skip to main content
SpringerLink
Log in

Determinants of drug response in camptothecin-11-resistant glioma cell lines

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Camptothecin-11 (CPT-11) is a new derivative of camptothecin, a plant alkaloid antitumor agent. Previous studies indicated that antitumor activity of CPT-11 was mediated through interaction of the drug with its target enzyme, DNA topoisomerase I (topo I).

To elucidate the mechanisms of CPT-11 resistance, we have characterized glioma cell lines (T98G/CPT-11, C6/CPT-11) selected from the wild types (T98G. C6) for acquired resistance to CPT-11. T98G/CPT-11 and C6/CPT-11 cells demonstrated 5.4- and 7.3-fold increases, respectively, in resistance to CPT-11.

Total glutathione S-transferase (GST) and GST-p activities were similar in CPT-11-sensitive and -resistant cells. No difference in intracellular accumulation of CPT-11 was observed between CPT-11-resistant and parental cells, indicating that an alteration in the uptake was not responsible for resistance. In addition, CPT-11-resistant cell lines showed no change in the total activity of Topo I, indicating an alteration in total Topo I activity was not responsible for resistance.

In contrast, significantly increased intracellular glutathione (GSH) levels were found in T98G/CPT-11 and C6/CPT-11 cells (4.3- and 2.1-fold). Furthermore, Topo I samples from T98G/CPT-11 and C6/CPT-11 cells were at least 4- and 2-fold more resistant to the inhibitory effect of the CPT-11 on the relaxation activity of Topo I than were Topo I samples from their respective parent lines. The resistance of the enzyme itself to the effects of CPT-11 may be responsible for the resistance to CPT-11. Thus, at least two distinct mechanisms have been selected for the CPT-11-resistant cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gallo RC, Whang-Peng J, Adamson RH: Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789–795, 1971

    Google Scholar 

  2. Gottlieb JA, Luce KJ: Treatment of malignant melanoma with camptothecin (NSC100880). Cancer Chemother Rep 56: 103–105, 1972

    Google Scholar 

  3. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase II study of camptothecin (NSC-100880) in the treatment of the advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95–101, 1972

    Google Scholar 

  4. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515–521, 1972

    Google Scholar 

  5. Matsuzaki T, Yokokura T, Mutai M, Turuo T: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308–312, 1988

    Google Scholar 

  6. Andoh I, Ishii K, Suzuki Y, Kusunoki Y, Takemoto Y, Okada K: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565–5569, 1987

    Google Scholar 

  7. Okamoto H, Saijo S: Preclinical trial from the standpoint of clinical trials. Jpn J Cancer Chemother 18: 1467–1475, 1991

    Google Scholar 

  8. Fukuoka M: A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 18: 1013–1019, 1991

    Google Scholar 

  9. Niitani H: An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 18: 607–612, 1991

    Google Scholar 

  10. Taguchi T: DNA topoisomerase inhibitor as chemother-apeutic drug — Clinical point of view. Jpn J Cancer Chemother 18: 1574–1578, 1991

    Google Scholar 

  11. Takeuchi S: An early phase II study of CPT-11 for gynocologic cancers. Jpn J Cancer Chemother 18: 579–584, 1991

    Google Scholar 

  12. Habig WH, Pabst MJ, Jakoby WB: Glutathione S-transferases. J Biol Chem 249: 7130–7139, 1974

    Google Scholar 

  13. Bradford MM: A rapid and sensitive method for the quantitation of micrgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976

    Google Scholar 

  14. Hissin PJ, Hilf R: A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74: 214–226, 1976

    Google Scholar 

  15. Chow KC, Johnson TL, Pearson GD: A novel method for the detection and quantitation of eukaryotic topoisomerase I. Biotechniques 3: 290–296, 1985

    Google Scholar 

  16. Takano H, Kohno K, Ono M, Ushida Y, Kuwano M: Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951–3957, 1991

    Google Scholar 

  17. Hsing YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular targets of the anti cancer drug camptothecin. Cancer Res 48: 1722–1726, 1988

    Google Scholar 

  18. Liu LF, Miller KG: Eukarytic DNA topoisomerase: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78: 3487–3491, 1981

    Google Scholar 

  19. Matsumoto Y, Sasaoka N, Tsuchida T, Fujiwara T, Nagao S, Ohmoto T: Fluorescent dye rhodamine 6G as a molecular probe to study drug resistance of C6 rat glioma cells. J Neurooncol 13: 217–222, 1992

    Google Scholar 

  20. Matsumoto Y, Sasaoka N, Tsuchida T, Fujiwara T, Nagao S: Quantitative analysis of glutathione S-transferase in human brain tumors, C6 rat glioma cells, and drug resistant C6 cells. In: Tabuchi (ed) Biological aspects of brain tumors. Tokyo: Springer-Verlag, 1991, pp 281–287

    Google Scholar 

  21. Andoh T, Okada K, Oguro M: Biological function of DNA topoisomerases and its implication in cancer chemotherapy. Jpn J Cancer Chemother 15: 1–14, 1988

    Google Scholar 

  22. Chen GL, Lie LF: DNA topoisomerases as therapeutic targets in cancer chemotherapy. Annu Rep Med Chem 21: 257–262, 1986

    Google Scholar 

  23. Lie LF, Lie CC, Albert BM: Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19: 697–707, 1980

    Google Scholar 

  24. Wang JC: DNA topoisomerases. Annu Rev Biochem 54: 665–697, 1985

    Google Scholar 

  25. Wang JC: Recent studies of DNA topoisomerases. Biochem Biophys Acta 909: 1–9, 1987

    Google Scholar 

  26. Tewey KM, Chen GL, Nelson EM, Lie LF: Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 9182–9187, 1984

    Google Scholar 

  27. Ross WE: DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 34: 4191–4195, 1985

    Google Scholar 

  28. Drlica K, Franco RJ: Inhibitors of DNA topoisomerases. Biochemistry. 27: 2253–2259, 1988

    Google Scholar 

  29. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K: Intercellular role of SN-38, a metabolite of the Camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187–4191, 1991

    Google Scholar 

  30. Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Kenneth DT, Saijo N: Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J Cancer Res 81: 527–535, 1990

    Google Scholar 

  31. Buller AL, Claper ML, Tew KD: Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol 31: 575–578, 1987

    Google Scholar 

  32. Smith MT, Evans CG, Doane SP, Castro VM, Tahir MK, Mannervik B: Denitrosation of 1.3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferase and its role in cellular resistance in rat brain tumor cells. Cancer Res 49: 2621–2625, 1989

    Google Scholar 

  33. Ochi T, Otsuka F, Takahashi K, Ohsawa M: Glutathione and metallothionein as cellular defense against cadmium toxicity in cultured Chinese hamster cells. Chem Biol Interact 65: 1–14, 1988

    Google Scholar 

  34. Eng WK, Mccabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Molec Pharmacol 38: 471–480, 1991

    Google Scholar 

  35. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Lie LY, Saijo N: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance 50: 5919–5929, 1990

    Google Scholar 

  36. Towatari M, Uto Y, Morishita Y, Tanimoto M, Kawashima K, Morishita Y, Ando K, Saitoh H: Enhanced expression of DNA topoisomerase II by recombinat human granulocyte colony-stimulating factor in human leukemia cells. Cancer Res 50: 7198–7202, 1990

    Google Scholar 

  37. Sugimoto Y, Tsukahara S, Ohhara T, Liu LF, Turuo T: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962–7965, 1990

    Google Scholar 

  38. Turuo T, Matsuzaki T, Matsushita M, Saitoh H, Yokokura H: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumorsin vitro andin vivo. Cancer Chemother Pharmacol 21: 71–74, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, Kagawa Medical School, Kagawa, Japan

    Yoshihito Matsumoto, Takashi Fujiwara & Seigo Nagao

Authors
  1. Yoshihito Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seigo Nagao
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matsumoto, Y., Fujiwara, T. & Nagao, S. Determinants of drug response in camptothecin-11-resistant glioma cell lines. J Neuro-Oncol 23, 1–8 (1995). https://doi.org/10.1007/BF01058453

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01058453

Key words

Search

Navigation